1. Executive Summary (Confidence: High)

Sophia Genetics (Nasdaq: SOPH) represents a paradigm shift in the application of artificial intelligence within the clinical diagnostic and biopharmaceutical sectors. By establishing a decentralized network that allows local hospitals and laboratories to maintain control over their patient samples while leveraging global-scale analytical power, the company has effectively democratized access to precision medicine.^[1] The organization’s primary asset, the SOPHiA DDM™ platform, serves as an analytical "operating system" that standardizes "noisy" genomic data, providing clinical-grade variant interpretation for over 500 core genomics customers globally.^[3] Financial performance in 2025 underscored the scalability of this model, with a 19% increase in revenue to $77.3 million and a significant expansion in adjusted gross margins to 74.2%, driven by the optimization of compute costs and high net dollar retention.^[4] Strategically, the firm is currently executing a major expansion into the North American market, solidified by partnerships with some of the largest integrated healthcare systems in the United States, which are projected to process tens of thousands of patients annually.^[4]